ICCC

Business Context and Reporting Period

ImmuCell Corporation (ICCC) is an animal health company focused on dairy and beef cattle, specifically targeting the first 30 days of life (scours prevention via the First Defense product line) and the first 30 days of lactation (mastitis treatment via the Re-Tain product line). This summary covers the unaudited quarterly period ended March 31, 2025.

Key Financial Metrics

Material Changes vs. Prior Period

• Profitability Turnaround: The company reported a net income of $1.45 million in Q1 2025, a swing of approximately $1.88 million compared to the net loss in Q1 2024. This was driven by a 46% increase in gross margin and a 14% reduction in operating expenses.
• Gross Margin Expansion: Gross margin percentage improved from 32% to 42%. Management attributes this to the remediation of production contamination events (last event in April 2024), optimized process yields, and price increases implemented in late 2023 and early 2025.
• Revenue Growth: Product sales increased 11% year-over-year, with domestic sales up 13%. The backlog of orders decreased from approximately $4.4 million at year-end 2024 to $4.0 million as of March 31, 2025.
• Insurance Recovery: Other income included a $426,587 insurance recovery related to business interruption losses from prior contamination events, contributing significantly to the net income.
• Expense Reduction: Product development expenses decreased 40% to $757,000 as the company idled certain activities for the Re-Tain product while awaiting FDA approval.

Guidance, Outlook, and Risks

• Re-Tain Regulatory Status: The company submitted a Non-Administrative NADA in January 2025. Approval is contingent on the resolution of inspectional observations at a contract manufacturer's facility (Form 483 issued in April 2025). Management anticipates no further impediments if observations are cleared but cannot forecast approval timing.
• Liquidity: Management projects existing cash and anticipated gross margins will fund operations for at least the next 12 months. The company continues to utilize an At-The-Market (ATM) offering for capital, generating net proceeds of approximately $270,000 between January and May 2025.
• Debt Covenants: The company is required to meet a minimum Debt Service Coverage (DSC) ratio of 1.35 for the year ending December 31, 2025. Previous covenants for 2023 and 2024 were waived by lenders due to poor performance.
• Production Risks: While contamination events have been remediated, the company notes risks regarding future equipment failures, supply chain disruptions, and the ability to maintain gross margins above 45%.
• Capital Expenditures: Large capital projects to expand First Defense capacity and build in-house Re-Tain filling capabilities have been deferred to conserve cash, though smaller necessary expenditures continue.

Investor Verification Checklist

• Debt Covenant Compliance: Verify the company's ability to meet the 1.35 DSC ratio for the fiscal year ending December 31, 2025, given the significant debt service obligations ($1.5M in 2025, $3.3M in 2026).
• Re-Tain FDA Timeline: Monitor the status of the contract manufacturer's Form 483 resolution and the subsequent FDA review of the NADA submission, as this is the critical path for the company's second major product line.
• Backlog Conversion: Assess the sustainability of sales growth as the order backlog ($4.0M) is reduced and the company transitions from fulfilling backlogged orders to meeting ongoing demand.
• Inventory Valuation: Review the Work-in-Process inventory levels ($5.76M), which represent 78% of total inventory, and the risk of obsolescence if Re-Tain approval is further delayed.
• Customer Concentration: Note that two distributors accounted for 81% of sales and 69% of accounts receivable in Q1 2025, creating significant concentration risk.